A Prospective, Multicentre, Cohort Study to Assess the Long Term Virological and Immunological Response of Dolutegravir Plus Lamivudine Dual Therapy in Patients with Suppressed HIV-RNA
Latest Information Update: 28 Dec 2018
At a glance
- Drugs Dolutegravir (Primary) ; Lamivudine (Primary)
- Indications HIV infections
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 28 Dec 2018 New trial record
- 31 Oct 2018 Results presented at the 14th International Congress on Drug Therapy and HIV Infection.